Emerging therapies for hemophilia: A new era of care and the role of the interdisciplinary team

Michelle Witkop; Susan Cutter; Joann Deutsche; Maria Santaella; Robin Chapman; Jennifer Lafranco; Angela Lambing

doi:10.1055/s-0034-1384636

Emerging therapies for hemophilia: A new era of care and the role of the interdisciplinary team

Michelle Witkop, Susan Cutter, Joann Deutsche, Maria Santaella, Robin Chapman, Jennifer Lafranco, Angela Lambing

Orthopedics

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.

Original language	English (US)
Pages (from-to)	790-802
Number of pages	13
Journal	Seminars in Thrombosis and Hemostasis
Volume	40
Issue number	7
DOIs	https://doi.org/10.1055/s-0034-1384636
State	Published - Oct 1 2014

Keywords

adherence
cultural
hemophilia
psychosocial
therapy transition

ASJC Scopus subject areas

Hematology
Cardiology and Cardiovascular Medicine

Access to Document

10.1055/s-0034-1384636

Cite this

@article{f42fa864c3cc42cab5473ac4e5964be5,

title = "Emerging therapies for hemophilia: A new era of care and the role of the interdisciplinary team",

abstract = "The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.",

keywords = "adherence, cultural, hemophilia, psychosocial, therapy transition",

author = "Michelle Witkop and Susan Cutter and Joann Deutsche and Maria Santaella and Robin Chapman and Jennifer Lafranco and Angela Lambing",

year = "2014",

month = oct,

day = "1",

doi = "10.1055/s-0034-1384636",

language = "English (US)",

volume = "40",

pages = "790--802",

journal = "Seminars in Thrombosis and Hemostasis",

issn = "0094-6176",

publisher = "Thieme Medical Publishers",

number = "7",

}

TY - JOUR

T1 - Emerging therapies for hemophilia

T2 - A new era of care and the role of the interdisciplinary team

AU - Witkop, Michelle

AU - Cutter, Susan

AU - Deutsche, Joann

AU - Santaella, Maria

AU - Chapman, Robin

AU - Lafranco, Jennifer

AU - Lambing, Angela

PY - 2014/10/1

Y1 - 2014/10/1

N2 - The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.

AB - The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.

KW - adherence

KW - cultural

KW - hemophilia

KW - psychosocial

KW - therapy transition

UR - http://www.scopus.com/inward/record.url?scp=84928541087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928541087&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1384636

DO - 10.1055/s-0034-1384636

M3 - Article

C2 - 25144753

AN - SCOPUS:84928541087

SN - 0094-6176

VL - 40

SP - 790

EP - 802

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

IS - 7

ER -

Emerging therapies for hemophilia: A new era of care and the role of the interdisciplinary team

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this